Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy

Archives of Ophthalmology

Volumn 125, Issue 6, 2007, Pages 751-756

  Finger, Paul T ^a,b   Chin, Kimberly ^a  

^a NEW YORK EYE CANCER CENTER   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMAGING SYSTEM; MALE; MICROANGIOPATHY; OPTICAL COHERENCE TOMOGRAPHY; PHOTOGRAPHY; PRIORITY JOURNAL; RETINA EDEMA; RETINA EXUDATE; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION; RETINA RADIATION TRAUMA; RETINOPATHY; SCANNING LASER OPHTHALMOSCOPY; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRACHYTHERAPY; CHOROID NEOPLASMS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MELANOMA; MIDDLE AGED; OPHTHALMOSCOPY; RADIATION INJURIES; RETINA; RETINAL DISEASES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 34250343012     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.6.751     Document Type: Article

References (20)

1. Bedford MA, Bedotto C, Macfaul PA. Radiation retinopathy after the application of a cobalt plaque: report of three cases. Br J Ophthalmol. 1970;54:505-509.
2. Finger PT, Berson A, Ng T, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys. 2002;54:1438-1445.
3. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys. 1994;30:765-773.
4. Foerster MH, Fried M, Wessing A, Meyer-Schwickerath G. Radiation retinopathy following treatment of choroid melanomas with 106Ru/106Rh applicators [in German]. Fortschr Ophthalmol. 1983;80:418-421.
5. Finger PT, Lynne AL. Ophthalmic brachytherapy: treatment of choroidal melanoma and retinoblastoma. In: Peyman GA, Meffert SA, Conway MD, eds. Vitreoretinal Surgical Techniques. 2nd ed. London, England: Informa Healthcare; 2007:452-468.
6. Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy: clinical, histopathological, ultrastructural and experimental correlations. Eye. 1991;5:239-251.
7. Gardiner TA, Amoaku WM, Archer DB. The combined effect of diabetes and ionizing radiation on the retinal vasculature of the rat. Curr Eye Res. 1993;12:1009-1014.
8. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89:730-738.
9. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
10. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158.
11. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37:148-150.
12. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-146.
13. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284.
14. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
15. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354-356.
16. Finger PT. Anti VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol. 2007;143:335-338.
17. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
18. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
19. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol. 2006;142:162-164.
20. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42:215-232.